BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Keeffe EB, Dieterich DT, Han SH, Jacobson IM, Martin P, Schiff ER, Tobias H, Wright TL. A treatment algorithm for the management of chronic hepatitis B virus infection in the United States: an update. Clin Gastroenterol Hepatol. 2006;4:936-962. [PMID: 16844425 DOI: 10.1016/j.cgh.2006.05.016] [Cited by in Crossref: 260] [Cited by in F6Publishing: 231] [Article Influence: 16.3] [Reference Citation Analysis]
Number Citing Articles
1 Chevaliez S, Pawlotsky J. Virological techniques for the diagnosis and monitoring of hepatitis B and C. Annals of Hepatology 2009;8:7-12. [DOI: 10.1016/s1665-2681(19)31804-6] [Cited by in Crossref: 11] [Article Influence: 0.8] [Reference Citation Analysis]
2 Mast EE, Ward JW. Hepatitis B vaccines. Vaccines. Elsevier; 2008. pp. 205-41. [DOI: 10.1016/b978-1-4160-3611-1.50017-9] [Cited by in Crossref: 5] [Article Influence: 0.4] [Reference Citation Analysis]
3 Martin P, Lau DT, Nguyen MH, Janssen HL, Dieterich DT, Peters MG, Jacobson IM. A Treatment Algorithm for the Management of Chronic Hepatitis B Virus Infection in the United States: 2015 Update. Clinical Gastroenterology and Hepatology 2015;13:2071-2087.e16. [DOI: 10.1016/j.cgh.2015.07.007] [Cited by in Crossref: 73] [Cited by in F6Publishing: 60] [Article Influence: 10.4] [Reference Citation Analysis]
4 Coffin CS, Lee SS. Treatment of HBeAg-positive patients with nucleos/tide analogues. Liver International 2009;29:116-24. [DOI: 10.1111/j.1478-3231.2008.01935.x] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
5 Cheruvu S, Marks K, Talal AH. Understanding the Pathogenesis and Management of Hepatitis B/HIV and Hepatitis B/Hepatitis C Virus Coinfection. Clinics in Liver Disease 2007;11:917-43. [DOI: 10.1016/j.cld.2007.08.007] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 1.0] [Reference Citation Analysis]
6 Tapper EB, Afdhal NH. Vibration-controlled transient elastography: a practical approach to the noninvasive assessment of liver fibrosis. Curr Opin Gastroenterol 2015;31:192-8. [PMID: 25730177 DOI: 10.1097/MOG.0000000000000169] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 1.8] [Reference Citation Analysis]
7 Croagh CMN, Bell SJ, Locarnini S, Desmond PV. Assessment of chronic hepatitis B: the importance of hepatitis B virus DNA testing: HBV DNA in assessment of CHB. Internal Medicine Journal 2012;42:170-5. [DOI: 10.1111/j.1445-5994.2011.02435.x] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
8 Mayer TK, Vargas RL, Knebel AE, Williams SA, Culver SP, Clark DM, King LR. Hepatitis B assays in serum, plasma and whole blood on filter paper. BMC Clin Pathol 2012;12:8. [PMID: 22606954 DOI: 10.1186/1472-6890-12-8] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
9 Qiu Q, Li Y, Duan XW, Yang LK, Chen Y, Li H, Wang L, Duan ZP. Impact of a new reimbursement program on hepatitis B antiviral medication cost and utilization in Beijing, China. PLoS One 2014;9:e109652. [PMID: 25329072 DOI: 10.1371/journal.pone.0109652] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 1.0] [Reference Citation Analysis]
10 Cotler SJ, Dhamija MK, Siqueira F, Bartram AH, Luc BJ, Layden TJ, Wong SS. Hepatitis B seroprevalence and disease characteristics in an urban Chinatown community. Clin Gastroenterol Hepatol 2009;7:776-80. [PMID: 19344787 DOI: 10.1016/j.cgh.2009.03.023] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 0.8] [Reference Citation Analysis]
11 Abreu RM, da Silva Ferreira C, Ferreira AS, Remor E, Nasser PD, Carrilho FJ, Ono SK. Assessment of Adherence to Prescribed Therapy in Patients with Chronic Hepatitis B. Infect Dis Ther 2016;5:53-64. [PMID: 26757720 DOI: 10.1007/s40121-015-0101-y] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
12 Feld JJ, Ayers M, El-ashry D, Mazzulli T, Tellier R, Heathcote EJ. Hepatitis B virus DNA prediction rules for hepatitis B e antigen–negative chronic hepatitis B. Hepatology 2007;46:1057-70. [DOI: 10.1002/hep.21811] [Cited by in Crossref: 60] [Cited by in F6Publishing: 57] [Article Influence: 4.0] [Reference Citation Analysis]
13 Gish RG, Locarnini S. Genotyping and genomic sequencing in clinical practice. Clin Liver Dis 2007;11:761-95, viii. [PMID: 17981228 DOI: 10.1016/j.cld.2007.08.008] [Cited by in Crossref: 13] [Cited by in F6Publishing: 8] [Article Influence: 0.9] [Reference Citation Analysis]
14 Ning LH, Hao J, Liao ZL, Zhou YY, Guo H, Zhao XY. A survey on the current trends in the management of hepatitis B in China. Eur J Gastroenterol Hepatol. 2012;24:884-889. [PMID: 22569081 DOI: 10.1097/meg.0b013e32835447fa] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
15 Wang H, Xue L, Yan R, Zhou Y, Wang MS, Cheng MJ, Hai-Jun Huang. Comparison of histologic characteristics of Chinese chronic hepatitis B patients with persistently normal or mildly elevated ALT. PLoS One. 2013;8:e80585. [PMID: 24260428 DOI: 10.1371/journal.pone.0080585] [Cited by in Crossref: 19] [Cited by in F6Publishing: 19] [Article Influence: 2.1] [Reference Citation Analysis]
16 Zhou J, Wang FD, Wang ML, Tao YC, Wu DB, Sheng YJ, Xiao GB, Chen XB, Chen X, Chen EQ. Antiviral Therapy for Chronic HBV Infection With Persistently Normal Alanine Aminotransferase: Controversy and Consensus. Front Med (Lausanne) 2021;8:717125. [PMID: 34527683 DOI: 10.3389/fmed.2021.717125] [Reference Citation Analysis]
17 Alter HJ. Management of hepatitis virus infections. Haemophilia 2008;14 Suppl 3:26-32. [PMID: 18510518 DOI: 10.1111/j.1365-2516.2008.01739.x] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
18 Koo JH, Lee MH, Kim SS, Kim DH, Kim IS, Lee KM, Yoo BM, Lee KJ, Kim JH, Cho SW, Cheong JY. Changes in serum histologic surrogate markers and procollagen III N-terminal peptide as independent predictors of HBeAg loss in patients with chronic hepatitis B during entecavir therapy. Clinical Biochemistry 2012;45:31-6. [DOI: 10.1016/j.clinbiochem.2011.09.023] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
19 Brook G, Soriano V, Bergin C. European guideline for the management of hepatitis B and C virus infections, 2010. Int J STD AIDS 2010;21:669-78. [DOI: 10.1258/ijsa.2010.010234] [Cited by in Crossref: 16] [Cited by in F6Publishing: 17] [Article Influence: 1.3] [Reference Citation Analysis]
20 Ahn SH, Heo J, Park JY, Woo HY, Lee HJ, Tak WY, Um SH, Yoon KT, Park SY, Kim CW, Kim HH, Han KH, Cho M. A 96-week randomized trial of switching to entecavir in patients who achieved virological suppression on lamivudine therapy. J Gastroenterol Hepatol 2016;31:865-71. [PMID: 26572068 DOI: 10.1111/jgh.13231] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
21 Umemura T, Tanaka E, Kiyosawa K, Kumada H. Mortality secondary to fulminant hepatic failure in patients with prior resolution of hepatitis B virus infection in Japan. Clin Infect Dis. 2008;47:e52-e56. [PMID: 18643758 DOI: 10.1086/590968] [Cited by in Crossref: 114] [Cited by in F6Publishing: 91] [Article Influence: 8.8] [Reference Citation Analysis]
22 Ayoub WS, Keeffe EB. Review article: current antiviral therapy of chronic hepatitis B. Aliment Pharmacol Ther. 2008;28:167-177. [PMID: 18466358 DOI: 10.1111/j.1365-2036.2008.03731.x] [Cited by in Crossref: 48] [Cited by in F6Publishing: 39] [Article Influence: 3.4] [Reference Citation Analysis]
23 Yoo BC, Kim JH, Kim TH, Koh KC, Um SH, Kim YS, Lee KS, Han BH, Chon CY, Han JY, Ryu SH, Kim HC, Byun KS, Hwang SG, Kim BI, Cho M, Yoo K, Lee HJ, Hwang JS, Kim YS, Lee YS, Choi SK, Lee YJ, Yang JM, Park JW, Lee MS, Kim DG, Chung YH, Cho SH, Choi JY, Kweon YO, Lee HY, Jeong SH, Yoo HW, Lee HS. Clevudine is highly efficacious in hepatitis B e antigen-negative chronic hepatitis B with durable off-therapy viral suppression. Hepatology 2007;46:1041-8. [PMID: 17647293 DOI: 10.1002/hep.21800] [Cited by in Crossref: 82] [Cited by in F6Publishing: 68] [Article Influence: 5.5] [Reference Citation Analysis]
24 Robotin MC, Kansil M, Howard K, George J, Tipper S, Dore GJ, Levy M, Penman AG. Antiviral therapy for hepatitis B-related liver cancer prevention is more cost-effective than cancer screening. J Hepatol. 2009;50:990-998. [PMID: 19303657 DOI: 10.1016/j.jhep.2008.12.022] [Cited by in Crossref: 34] [Cited by in F6Publishing: 36] [Article Influence: 2.6] [Reference Citation Analysis]
25 Mangia A, Antonucci F, Brunetto M, Capobianchi M, Fagiuoli S, Guido M, Farci P, Lampertico P, Marzano A, Niro G. The use of molecular assays in the management of viral hepatitis. Dig Liver Dis. 2008;40:395-404. [PMID: 18321798 DOI: 10.1016/j.dld.2007.12.016] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 0.8] [Reference Citation Analysis]
26 Chan HL, Tse CH, Mo F, Koh J, Wong VW, Wong GL, Lam Chan S, Yeo W, Sung JJ, Mok TS. High viral load and hepatitis B virus subgenotype ce are associated with increased risk of hepatocellular carcinoma. J Clin Oncol. 2008;26:177-182. [PMID: 18182659 DOI: 10.1200/jco.2007.13.2043] [Cited by in Crossref: 207] [Cited by in F6Publishing: 81] [Article Influence: 14.8] [Reference Citation Analysis]
27 Akima T, Tamano M, Yamagishi H, Kubota K, Fujimori T, Hiraishi H. Surgical treatment of HCC in a patient with lamivudine-resistant hepatitis B cirrhosis with adefovir dipivoxil. World J Hepatol 2010; 2(8): 318-321 [PMID: 21161015 DOI: 10.4254/wjh.v2.i8.318] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
28 Lau GKK. HBeAg-positive chronic hepatitis B: why do I treat my patients with pegylated interferon. Liver International 2009;29:125-9. [DOI: 10.1111/j.1478-3231.2008.01946.x] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.2] [Reference Citation Analysis]
29 Nishida T, Kobashi H, Fujioka S, Fujio K, Takaguchi K, Ikeda H, Kawaguchi M, Ando M, Araki Y, Higashi T. A prospective and comparative cohort study on efficacy and drug resistance during long-term lamivudine treatment for various stages of chronic hepatitis B and cirrhosis. J Gastroenterol Hepatol. 2008;23:794-803. [PMID: 18086120 DOI: 10.1111/j.1440-1746.2007.05240.x] [Cited by in Crossref: 18] [Cited by in F6Publishing: 19] [Article Influence: 1.2] [Reference Citation Analysis]
30 Papatheodoridis GV, Manesis EK, Manolakopoulos S, Archimandritis AJ. Serum hepatitis B virus-DNA cutoff levels in hepatitis B e antigen–negative chronic hepatitis B virus infection. Hepatology 2007;46:606-7. [DOI: 10.1002/hep.21864] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
31 Pan CQ, Han GR, Jiang HX, Zhao W, Cao MK, Wang CM, Yue X, Wang GJ. Telbivudine prevents vertical transmission from HBeAg-positive women with chronic hepatitis B. Clin Gastroenterol Hepatol. 2012;10:520-526. [PMID: 22343511 DOI: 10.1016/j.cgh.2012.01.019] [Cited by in Crossref: 109] [Cited by in F6Publishing: 103] [Article Influence: 10.9] [Reference Citation Analysis]
32 Enomoto M, Tamori A, Kohmoto MT, Hayashi T, Jomura H, Habu D, Sakaguchi H, Takeda T, Kawada N, Seki S. Lamivudine and IFN-beta sequential therapy in HBe antigen-positive patients with chronic hepatitis B virus genotype C infection. J Interferon Cytokine Res. 2007;27:201-207. [PMID: 17348818 DOI: 10.1089/jir.2006.0140] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 0.5] [Reference Citation Analysis]
33 Jin BX, Zhang YH, Jin WJ, Sun XY, Qiao GF, Wei YY, Sun LB, Zhang WH, Li N. MicroRNA panels as disease biomarkers distinguishing hepatitis B virus infection caused hepatitis and liver cirrhosis. Sci Rep. 2015;5:15026. [PMID: 26456479 DOI: 10.1038/srep15026] [Cited by in Crossref: 23] [Cited by in F6Publishing: 22] [Article Influence: 3.3] [Reference Citation Analysis]
34 Chang TT, Suh DJ. Current approaches for treating chronic hepatitis B: when to start, what to start with, and when to stop. Hepatol Int 2008;2:19-27. [PMID: 19669295 DOI: 10.1007/s12072-008-9059-0] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
35 Zoulim F. Hepatitis B virus resistance to antiviral drugs: where are we going? Liver Int. 2011;31 Suppl 1:111-116. [PMID: 21205147 DOI: 10.1111/j.1478-3231.2010.02399.x.] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
36 Brunetto MR, Moriconi F, Bonino F, Lau GK, Farci P, Yurdaydin C, Piratvisuth T, Luo K, Wang Y, Hadziyannis S, Wolf E, McCloud P, Batrla R, Marcellin P. Hepatitis B virus surface antigen levels: a guide to sustained response to peginterferon alfa-2a in HBeAg-negative chronic hepatitis B. Hepatology. 2009;49:1141-1150. [PMID: 19338056 DOI: 10.1002/hep.22760] [Cited by in Crossref: 336] [Cited by in F6Publishing: 308] [Article Influence: 25.8] [Reference Citation Analysis]
37 Cheng PN, Chang TT. Entecavir: a potent antiviral with minimal long-term resistance in nucleoside-naive chronic hepatitis B patients. Expert Rev Anti Infect Ther. 2008;6:569-579. [PMID: 18847396 DOI: 10.1586/14787210.6.5.569] [Cited by in Crossref: 15] [Cited by in F6Publishing: 17] [Article Influence: 1.1] [Reference Citation Analysis]
38 Hou J, Schilling R, Janssen HL, Hansen BE, Heijtink R, Sablon E, Williams R, Lau GK, Schalm SW, Naoumov NV. Genetic characteristics of hepatitis B virus genotypes as a factor for interferon-induced HBeAg clearance. J Med Virol. 2007;79:1055-1063. [PMID: 17596838 DOI: 10.1002/jmv.20935] [Cited by in Crossref: 29] [Cited by in F6Publishing: 27] [Article Influence: 1.9] [Reference Citation Analysis]
39 Van Leeuwen DJ, Balabaud C, Crawford JM, Bioulac–sage P, Dhillon AP. A Clinical and Histopathologic Perspective on Evolving Noninvasive and Invasive Alternatives for Liver Biopsy. Clinical Gastroenterology and Hepatology 2008;6:491-6. [DOI: 10.1016/j.cgh.2008.02.023] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 0.5] [Reference Citation Analysis]
40 Valsamakis A. Molecular testing in the diagnosis and management of chronic hepatitis B. Clin Microbiol Rev. 2007;20:426-439, table of contents. [PMID: 17630333 DOI: 10.1128/cmr.00009-07] [Cited by in Crossref: 86] [Cited by in F6Publishing: 32] [Article Influence: 5.7] [Reference Citation Analysis]
41 Yao G, Chen C, Lu W, Ren H, Tan D, Wang Y, Xu D, Jiang Z, Liu J, Xu D. Efficacy and safety of entecavir compared to lamivudine in nucleoside-naïve patients with chronic hepatitis B: a randomized double-blind trial in China. Hepatol Int. 2007;1:365-372. [PMID: 19669331 DOI: 10.1007/s12072-007-9009-2] [Cited by in Crossref: 32] [Cited by in F6Publishing: 32] [Article Influence: 2.1] [Reference Citation Analysis]
42 Buey LG, Mateos FG, Oteroa RM. Interferón en la hepatitis B. Enfermedades Infecciosas y Microbiología Clínica 2008;26:19-31. [DOI: 10.1016/s0213-005x(08)76516-9] [Cited by in Crossref: 3] [Article Influence: 0.2] [Reference Citation Analysis]
43 Crockett SD, Kaltenbach T, Keeffe EB. Do We Still Need a Liver Biopsy? Are the Serum Fibrosis Tests Ready for Prime Time? Clinics in Liver Disease 2006;10:513-34. [DOI: 10.1016/j.cld.2006.08.009] [Cited by in Crossref: 9] [Cited by in F6Publishing: 11] [Article Influence: 0.6] [Reference Citation Analysis]
44 Cho Y, Song B. New Insight for HBV DNA and HBsAg Quantitation during Antiviral Therapy in Patients with Chronic Hepatitis B. Korean J Gastroenterol 2011;57:144. [DOI: 10.4166/kjg.2011.57.3.144] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
45 Liaw YF. Towards a rational treatment strategy for chronic hepatitis B. Hepatol Int 2007;1:285-6. [PMID: 19669351 DOI: 10.1007/s12072-007-9005-6] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
46 Sanai FM, Keeffe EB. Liver biopsy for histological assessment: The case against. Saudi J Gastroenterol. 2010;16:124-132. [PMID: 20339187 DOI: 10.4103/1319-3767.61244] [Cited by in Crossref: 37] [Cited by in F6Publishing: 37] [Article Influence: 3.1] [Reference Citation Analysis]
47 Cheng SQ. Influence of non-pathological factors on ALT measurements. Shijie Huaren Xiaohua Zazhi 2017; 25(34): 3005-3020 [DOI: 10.11569/wcjd.v25.i34.3005] [Reference Citation Analysis]
48 Manesis EK. The natural history of chronic HBV infection. Curr hepatitis rep 2009;8:10-7. [DOI: 10.1007/s11901-009-0002-1] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
49 Rustgi V, Carriero D, Bachtold M, Zeldin G. Update on Chronic Hepatitis B. The Journal for Nurse Practitioners 2010;6:631-9. [DOI: 10.1016/j.nurpra.2010.01.004] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
50 Fung J, Lai C, But D, Wong D, Cheung T, Yuen M. Prevalence of Fibrosis and Cirrhosis in Chronic Hepatitis B: Implications for Treatment and Management. Am J Gastroenterology 2008;103:1421-6. [DOI: 10.1111/j.1572-0241.2007.01751.x] [Cited by in Crossref: 36] [Cited by in F6Publishing: 34] [Article Influence: 2.6] [Reference Citation Analysis]
51 Kao JH. Diagnosis of hepatitis B virus infection through serological and virological markers. Expert Rev Gastroenterol Hepatol. 2008;2:553-562. [PMID: 19072403 DOI: 10.1586/17474124.2.4.553] [Cited by in Crossref: 71] [Cited by in F6Publishing: 61] [Article Influence: 5.5] [Reference Citation Analysis]
52 Xu Z, Liu L, Pan X, Wei K, Wei M, Liu L, Yang H, Liu Q. Serum Golgi protein 73 (GP73) is a diagnostic and prognostic marker of chronic HBV liver disease. Medicine (Baltimore). 2015;94:e659. [PMID: 25816035 DOI: 10.1097/md.0000000000000659] [Cited by in Crossref: 23] [Cited by in F6Publishing: 19] [Article Influence: 3.3] [Reference Citation Analysis]
53 Weisberg IS, Brown RS, Sigal SH. Hepatitis B and End-Stage Liver Disease. Clinics in Liver Disease 2007;11:893-916. [DOI: 10.1016/j.cld.2007.08.009] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 0.8] [Reference Citation Analysis]
54 Gish RG. Improving outcomes for patients with chronic hepatitis B. Curr Gastroenterol Rep. 2007;9:14-22. [PMID: 17335673 DOI: 10.1007/s11894-008-0016-9] [Cited by in Crossref: 5] [Cited by in F6Publishing: 8] [Article Influence: 0.3] [Reference Citation Analysis]
55 Kim IS, Mun JI, Koo JH, Kang CJ, Bak JK, Cheong JY, Cho SW. [Entecavir therapy for patients with hepatitis B virus-related decompensated cirrhosis]. Korean J Gastroenterol. 2012;59:224-231. [PMID: 22460571 DOI: 10.4166/kjg.2012.59.3.224] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
56 Giannini EG, Torre F, Basso M, Feasi M, Boni S, Grasso A, De Leo P, Dodi F, Marazzi MG, Azzola E, Bartolacci V, Percario G, Beltrame A, Borro P, Savarino V, Picciotto A; Ligurian Hepatitis B Virus Study Group. A significant proportion of patients with chronic hepatitis B who are candidates for antiviral treatment are untreated: A region-wide survey in Italy. J Clin Gastroenterol 2009;43:1001-7. [PMID: 19318981 DOI: 10.1097/MCG.0b013e31818e876f] [Cited by in Crossref: 18] [Cited by in F6Publishing: 10] [Article Influence: 1.5] [Reference Citation Analysis]
57 Davila M, Bresalier RS. Gastrointestinal complications of oncologic therapy. Nat Clin Pract Gastroenterol Hepatol. 2008;5:682-696. [PMID: 18941434 DOI: 10.1038/ncpgasthep1277] [Cited by in Crossref: 47] [Cited by in F6Publishing: 30] [Article Influence: 3.4] [Reference Citation Analysis]
58 Dore GJ, Guan R, Wasim Jafri SM, Sarin SV, Keeffe EB. Management of chronic hepatitis B in challenging patient populations. Liver International 2006;26:38-46. [DOI: 10.1111/j.1478-3231.2006.01375.x] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 0.5] [Reference Citation Analysis]
59 Montineri A, Nigro L, La Rosa R, Iacobello C, Larocca L, Cappello E, Fiumara PF, Di Raimondo F, Fatuzzo F. Treatment induced seroconversion to HBsAb following HBV reactivation in the immunosuppressed haematology and oncology patient: a clinical survey of 5 cases in Catania, Italy. J Clin Virol 2011;52:284-7. [PMID: 21906994 DOI: 10.1016/j.jcv.2011.08.007] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
60 Hadziyannis SJ. Unrevealing the natural course of the so-called “inactive HBsAg or HBV carrier state”. Hepatol Int. 2007;1:281-284. [PMID: 19669350 DOI: 10.1007/s12072-007-9004-7] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 1.4] [Reference Citation Analysis]
61 Buti M, Rodríguez Frías F, Calleja JL, Jardí R, Pons F, Crespo J, Casanovas T, Enríquez J, Carnicer F, Romero M, García Bengoechea M, Prieto M, García Samaniego J, Miras M, Pérez Roldán F, Rueda M, Esteban R. [Adefovir dipivoxil compassionate use program in Spain: efficacy and resistance analysis]. Med Clin (Barc) 2007;129:566-70. [PMID: 17988612 DOI: 10.1157/13111710] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
62 Wong GL, Wong VW, Choi PC, Chan AW, Chim AM, Yiu KK, Chan HY, Chan FK, Sung JJ, Chan HL. Clinical factors associated with liver stiffness in hepatitis B e antigen-positive chronic hepatitis B patients. Clin Gastroenterol Hepatol. 2009;7:227-233. [PMID: 19121647 DOI: 10.1016/j.cgh.2008.10.023] [Cited by in Crossref: 53] [Cited by in F6Publishing: 59] [Article Influence: 3.8] [Reference Citation Analysis]
63 Yan Y, Mai L, Zheng YB, Zhang SQ, Xu WX, Gao ZL, Ke WM. What MELD score mandates use of entecavir for ACLF-HBV HBeAg-negative patients? World J Gastroenterol 2012; 18(33): 4604-4609 [PMID: 22969236 DOI: 10.3748/wjg.v18.i33.4604] [Cited by in CrossRef: 7] [Cited by in F6Publishing: 8] [Article Influence: 0.7] [Reference Citation Analysis]
64 Marinaki S, Kolovou K, Sakellariou S, Boletis JN, Delladetsima IK. Hepatitis B in renal transplant patients. World J Hepatol 2017; 9(25): 1054-1063 [PMID: 28951777 DOI: 10.4254/wjh.v9.i25.1054] [Cited by in Crossref: 9] [Cited by in F6Publishing: 5] [Article Influence: 1.8] [Reference Citation Analysis]
65 Goulis I, Dalekos GN. Entecavir monotherapy for lamivudine-refractory chronic hepatitis B. Expert Rev Anti Infect Ther 2008;6:855-9. [PMID: 19053898 DOI: 10.1586/14787210.6.6.855] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 0.4] [Reference Citation Analysis]
66 Poddar U, Yachha SK, Agarwal J, Krishnani N. Cure for immune-tolerant hepatitis B in children: is it an achievable target with sequential combo therapy with lamivudine and interferon? J Viral Hepat. 2013;20:311-316. [PMID: 23565612 DOI: 10.1111/jvh.12007] [Cited by in Crossref: 24] [Cited by in F6Publishing: 24] [Article Influence: 2.4] [Reference Citation Analysis]
67 Schiff E, Simsek H, Lee WM, Chao YC, Sette H Jr, Janssen HL, Han SH, Goodman Z, Yang J, Brett-Smith H, Tamez R. Efficacy and safety of entecavir in patients with chronic hepatitis B and advanced hepatic fibrosis or cirrhosis. Am J Gastroenterol. 2008;103:2776-2783. [PMID: 18721244 DOI: 10.1111/j.1572-0241.2008.02086.x] [Cited by in Crossref: 85] [Cited by in F6Publishing: 80] [Article Influence: 6.1] [Reference Citation Analysis]
68 Cheng Z, Lin P, Cheng N. HBV/HIV Coinfection: Impact on the Development and Clinical Treatment of Liver Diseases. Front Med (Lausanne) 2021;8:713981. [PMID: 34676223 DOI: 10.3389/fmed.2021.713981] [Reference Citation Analysis]
69 Rodríguez M, González-Diéguez ML. [Clinical management of patients with chronic hepatitis B virus infection]. Enferm Infecc Microbiol Clin 2008;26 Suppl 7:56-65. [PMID: 19100232 DOI: 10.1016/s0213-005x(08)76520-0] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
70 Kim HJ, Park JH, Park DI, Cho YK, Sohn CI, Jeon WK, Kim BI. Rescue therapy for lamivudine-resistant chronic hepatitis B: comparison between entecavir 1.0 mg monotherapy, adefovir monotherapy and adefovir add-on lamivudine combination therapy. J Gastroenterol Hepatol 2010;25:1374-80. [PMID: 20659226 DOI: 10.1111/j.1440-1746.2010.06381.x] [Cited by in Crossref: 47] [Cited by in F6Publishing: 46] [Article Influence: 3.9] [Reference Citation Analysis]
71 Andreani T, Serfaty L, Mohand D, Dernaika S, Wendum D, Chazouillères O, Poupon R. Chronic hepatitis B virus carriers in the immunotolerant phase of infection: histologic findings and outcome. Clin Gastroenterol Hepatol. 2007;5:636-641. [PMID: 17428739 DOI: 10.1016/j.cgh.2007.01.005] [Cited by in Crossref: 77] [Cited by in F6Publishing: 71] [Article Influence: 5.1] [Reference Citation Analysis]
72 Marcellin P, Sung J, Piratvisuth T. Avoiding and managing lamivudine resistance in chronic hepatitis B: current approaches and potential strategies including pegylated interferon. Liver International 2010;30:657-68. [DOI: 10.1111/j.1478-3231.2010.02207.x] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 0.5] [Reference Citation Analysis]
73 Papatheodoridis GV, Manolakopoulos S, Dusheiko G, Archimandritis AJ. Therapeutic strategies in the management of patients with chronic hepatitis B virus infection. Lancet Infect Dis. 2008;8:167-178. [PMID: 18053766 DOI: 10.1016/s1473-3099(07)70264-5] [Cited by in Crossref: 138] [Cited by in F6Publishing: 55] [Article Influence: 9.2] [Reference Citation Analysis]
74 Zoulim F. Hepatitis B virus resistance to antiviral drugs: where are we going? Liver Int. 2011;31 Suppl 1:111-116. [PMID: 21205147 DOI: 10.1111/j.1478-3231.2010.02399.x] [Cited by in Crossref: 78] [Cited by in F6Publishing: 82] [Article Influence: 7.1] [Reference Citation Analysis]
75 Muñoz Bertrán E, Pérez Ceballos E, Gómez Espín R, Ortega González I. [Hepatitis B reactivation in an HbsAg-negative/anti-HBc-positive patient with B-cell non-Hodgkin lymphoma receiving chemotherapy with rituximab]. Gastroenterol Hepatol. 2010;33:377-381. [PMID: 20363054 DOI: 10.1016/j.gastrohep.2010.01.010] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
76 Hay JE. Liver disease in pregnancy. Hepatology. 2008;47:1067-1076. [PMID: 18265410 DOI: 10.1002/hep.22130] [Cited by in Crossref: 201] [Cited by in F6Publishing: 130] [Article Influence: 14.4] [Reference Citation Analysis]
77 Chan HL, Jia J. Chronic hepatitis B in Asia-new insights from the past decade. J Gastroenterol Hepatol. 2011;26 Suppl 1:131-137. [PMID: 21199524 DOI: 10.1111/j.1440-1746.2010.06544.x] [Cited by in Crossref: 54] [Cited by in F6Publishing: 50] [Article Influence: 4.9] [Reference Citation Analysis]
78 Planas R, Morillas RM. Tratamiento de la infección por el virus de la hepatitis B. Estado actual y perspectivas. Gastroenterología y Hepatología 2008;31:349-55. [DOI: 10.1157/13123603] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
79 Post SE, Sodhi NK, Peng CH, Wan K, Pollack HJ. A simulation shows that early treatment of chronic hepatitis B infection can cut deaths and be cost-effective. Health Aff (Millwood) 2011;30:340-8. [PMID: 21289356 DOI: 10.1377/hlthaff.2008.0905] [Cited by in Crossref: 20] [Cited by in F6Publishing: 21] [Article Influence: 1.8] [Reference Citation Analysis]
80 Fournier C, Zoulim F. [Combination therapy in chronic hepatitis B]. Gastroenterol Clin Biol 2008;32:S42-9. [PMID: 18662609 DOI: 10.1016/S0399-8320(08)73264-0] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
81 Brook G, Bhagani S, Kulasegaram R, Torkington A, Mutimer D, Hodges E, Hesketh L, Farnworth S, Sullivan V, Gore C, Devitt E, Sullivan AK; Clinical Effectiveness Group British Association for Sexual Health and HIV. United Kingdom National Guideline on the Management of the viral hepatitides A, B and C 2015. Int J STD AIDS 2016;27:501-25. [PMID: 26745988 DOI: 10.1177/0956462415624250] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.2] [Reference Citation Analysis]
82 Dusheiko G. Treatment of HBeAg positive chronic hepatitis B: interferon or nucleoside analogues. Liver Int. 2013;33 Suppl 1:137-150. [PMID: 23286858 DOI: 10.1111/liv.12078] [Cited by in Crossref: 29] [Cited by in F6Publishing: 26] [Article Influence: 3.2] [Reference Citation Analysis]
83 Pawlotsky JM. [Virologic techniques for the diagnosis and monitoring of hepatitis B]. Gastroenterol Clin Biol. 2008;32:S56-S63. [PMID: 18662611 DOI: 10.1016/s0399-8320(08)73266-4] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.2] [Reference Citation Analysis]
84 Shafi MA, Bresalier RS. The gastrointestinal complications of oncologic therapy. Gastroenterol Clin North Am 2010;39:629-47. [PMID: 20951921 DOI: 10.1016/j.gtc.2010.08.004] [Cited by in Crossref: 23] [Cited by in F6Publishing: 15] [Article Influence: 2.1] [Reference Citation Analysis]
85 Song MJ, Song DS, Kim HY, Yoo SH, Bae SH, Choi JY, Yoon SK, Paik YH, Lee JS, Lee HW, Kim HJ. Durability of viral response after off-treatment in HBeAg positive chronic hepatitis B. World J Gastroenterol 2012; 18(43): 6277-6283 [PMID: 23180949 DOI: 10.3748/wjg.v18.i43.6277] [Cited by in CrossRef: 27] [Cited by in F6Publishing: 28] [Article Influence: 2.7] [Reference Citation Analysis]
86 Yin J, Ji Z, Liang P, Wu Q, Cui F, Wang F, Liang X, Zhuang G. The doses of 10 μg should replace the doses of 5 μg in newborn hepatitis B vaccination in China: A cost-effectiveness analysis. Vaccine 2015;33:3731-8. [PMID: 26057138 DOI: 10.1016/j.vaccine.2015.05.082] [Cited by in Crossref: 16] [Cited by in F6Publishing: 14] [Article Influence: 2.3] [Reference Citation Analysis]
87 Woo HY, Choi JY, Yoon SK, Suh DJ, Paik SW, Han KH, Um SH, Kim BI, Lee HJ, Cho M, Lee CK, Kim DJ, Hwang JS. Rescue therapy with adefovir in decompensated liver cirrhosis patients with lamivudine-resistant hepatitis B virus. Clin Mol Hepatol 2014;20:168-76. [PMID: 25032183 DOI: 10.3350/cmh.2014.20.2.168] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
88 Yıldız O, Aygen B, Demirtürk N, Demirdal T, Inan D, Yıldırmak T, Kantürk A, Tütüncü E, Group HBS. Lamivudine resistance mutations in patients infected with hepatitis B virus genotype D. World J Gastroenterol 2011; 17(45): 4987-4992 [PMID: 22174548 DOI: 10.3748/wjg.v17.i45.4987] [Cited by in CrossRef: 2] [Cited by in F6Publishing: 4] [Article Influence: 0.2] [Reference Citation Analysis]
89 Tong MJ, Hsien C, Hsu L, Sun HE, Blatt LM. Treatment recommendations for chronic hepatitis B: an evaluation of current guidelines based on a natural history study in the United States. Hepatology. 2008;48:1070-1078. [PMID: 18688879 DOI: 10.1002/hep.22476] [Cited by in Crossref: 66] [Cited by in F6Publishing: 58] [Article Influence: 4.7] [Reference Citation Analysis]
90 Fan L, Owusu-Edusei K Jr, Schillie SF, Murphy TV. Cost-effectiveness of testing hepatitis B-positive pregnant women for hepatitis B e antigen or viral load. Obstet Gynecol. 2014;123:929-937. [PMID: 24785842 DOI: 10.1097/aog.0000000000000124] [Cited by in Crossref: 21] [Cited by in F6Publishing: 13] [Article Influence: 3.0] [Reference Citation Analysis]
91 Papatheodoridis GV. Ethics Related to Liver Biopsies and Antiviral Therapies in Chronic Viral Hepatitis. Dig Dis 2007;26:59-65. [DOI: 10.1159/000109389] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.2] [Reference Citation Analysis]
92 Keeffe EB. Hepatitis B: Explosion of New Knowledge. Gastroenterology 2007;133:1718-21. [DOI: 10.1053/j.gastro.2007.09.048] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
93 Nguyen G, Garcia RT, Nguyen N, Trinh H, Keeffe EB, Nguyen MH. Clinical course of hepatitis B virus infection during pregnancy. Aliment Pharmacol Ther. 2009;29:755-764. [PMID: 19183158 DOI: 10.1111/j.1365-2036.2009.03932.x] [Cited by in Crossref: 57] [Cited by in F6Publishing: 54] [Article Influence: 4.4] [Reference Citation Analysis]
94 Ghozy S, Nam NH, Radwan I, Karimzadeh S, Tieu TM, Hashan MR, Abbas AS, Eid PS, Vuong NL, Khang NV, Elgabalawy E, Sayed AK, Hoa PTL, Huy NT. Therapeutic efficacy of hepatitis B virus vaccine in treatment of chronic HBV infections: A systematic review and meta-analysis. Rev Med Virol 2020;30:e2089. [PMID: 31811678 DOI: 10.1002/rmv.2089] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
95 Maida I, Soriano V, Castellares C, Ramos B, Sotgiu G, Martin-Carbonero L, Barreiro P, Rivas P, González-Lahoz J, Núñez M. Liver fibrosis in HIV-infected patients with chronic hepatitis B extensively exposed to antiretroviral therapy with anti-HBV activity. HIV Clin Trials 2006;7:246-50. [PMID: 17162318 DOI: 10.1310/hct0705-246] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 1.0] [Reference Citation Analysis]
96 Zhang J, Du X, Zhou Z, Lv F, Yu Y. Spleen thickness can predict significant liver pathology in patients with chronic hepatitis B with persistently normal alanine aminotransferase or minimally raised alanine aminotransferase: a retrospective study. J Int Med Res 2019;47:122-32. [PMID: 30213226 DOI: 10.1177/0300060518796760] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
97 Chao SD, Chang ET, Le PV, Prapong W, Kiernan M, So SKS. The Jade Ribbon Campaign: A Model Program for Community Outreach and Education to Prevent Liver Cancer in Asian Americans. J Immigrant Minority Health 2009;11:281-90. [DOI: 10.1007/s10903-007-9094-2] [Cited by in Crossref: 44] [Cited by in F6Publishing: 42] [Article Influence: 2.9] [Reference Citation Analysis]
98 Bacon BR. Workforce issues in hepatology: What is needed? Hepatology 2008;47:1801-4. [DOI: 10.1002/hep.22276] [Cited by in Crossref: 11] [Cited by in F6Publishing: 7] [Article Influence: 0.8] [Reference Citation Analysis]
99 Tsang PS, Trinh H, Garcia RT, Phan JT, Ha NB, Nguyen H, Nguyen K, Keeffe EB, Nguyen MH. Significant prevalence of histologic disease in patients with chronic hepatitis B and mildly elevated serum alanine aminotransferase levels. Clin Gastroenterol Hepatol. 2008;6:569-574. [PMID: 18455697 DOI: 10.1016/j.cgh.2008.02.037] [Cited by in Crossref: 55] [Cited by in F6Publishing: 53] [Article Influence: 3.9] [Reference Citation Analysis]
100 Marzano A, Angelucci E, Andreone P, Brunetto M, Bruno R, Burra P, Caraceni P, Daniele B, Di Marco V, Fabrizi F. Prophylaxis and treatment of hepatitis B in immunocompromised patients. Dig Liver Dis. 2007;39:397-408. [PMID: 17382608 DOI: 10.1016/j.dld.2006.12.017] [Cited by in Crossref: 152] [Cited by in F6Publishing: 154] [Article Influence: 10.1] [Reference Citation Analysis]
101 Sherman M, Yurdaydin C, Simsek H, Silva M, Liaw YF, Rustgi VK, Sette H, Tsai N, Tenney DJ, Vaughan J. Entecavir therapy for lamivudine-refractory chronic hepatitis B: improved virologic, biochemical, and serology outcomes through 96 weeks. Hepatology. 2008;48:99-108. [PMID: 18537189 DOI: 10.1002/hep.22323] [Cited by in Crossref: 122] [Cited by in F6Publishing: 110] [Article Influence: 8.7] [Reference Citation Analysis]
102 Van Damme P, Ward JW, Shouval D, Zanetti A. Hepatitis B Vaccines. Plotkin's Vaccines. Elsevier; 2018. pp. 342-374.e17. [DOI: 10.1016/b978-0-323-35761-6.00025-0] [Cited by in Crossref: 6] [Article Influence: 1.5] [Reference Citation Analysis]
103 Chan HL, Wong VW, Tse AM, Tse CH, Chim AM, Chan HY, Wong GL, Sung JJ. Serum hepatitis B surface antigen quantitation can reflect hepatitis B virus in the liver and predict treatment response. Clin Gastroenterol Hepatol. 2007;5:1462-1468. [PMID: 18054753 DOI: 10.1016/j.cgh.2007.09.005] [Cited by in Crossref: 246] [Cited by in F6Publishing: 240] [Article Influence: 17.6] [Reference Citation Analysis]
104 Zoulim F, Perrillo R. Hepatitis B: reflections on the current approach to antiviral therapy. J Hepatol. 2008;48 Suppl 1:S2-S19. [PMID: 18304680 DOI: 10.1016/j.jhep.2008.01.011] [Cited by in Crossref: 107] [Cited by in F6Publishing: 106] [Article Influence: 7.6] [Reference Citation Analysis]
105 Enomoto M, Tamori A, Kohmoto MT, Hayashi T, Morikawa H, Jomura H, Sakaguchi H, Habu D, Kawada N, Shiomi S. Optimal duration of additional therapy after biochemical and virological responses to lamivudine in patients with HBeAg-negative chronic hepatitis B: a randomized trial. Hepatol Res. 2008;38:954-959. [PMID: 18498358 DOI: 10.1111/j.1872-034x.2008.00378.x] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
106 Fung J, Lai CL, Yuen MF. LB80380: a promising new drug for the treatment of chronic hepatitis B. Expert Opin Investig Drugs. 2008;17:1581-1588. [PMID: 18808318 DOI: 10.1517/13543784.17.10.1581] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 1.2] [Reference Citation Analysis]
107 Zhang Q, Cheng ML, Liu Q, Mu M, Zhang YY, Liu BY. Efficacy of entecavir in nucleoside-naïve patients with hepatitis B e antigen-positive chronic hepatitis B. Shijie Huaren Xiaohua Zazhi 2009; 17(27): 2846-2849 [DOI: 10.11569/wcjd.v17.i27.2846] [Cited by in CrossRef: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
108 Gish RG, Lok AS, Chang T, de Man RA, Gadano A, Sollano J, Han K, Chao Y, Lee S, Harris M, Yang J, Colonno R, Brett–smith H. Entecavir Therapy for up to 96 Weeks in Patients With HBeAg-Positive Chronic Hepatitis B. Gastroenterology 2007;133:1437-44. [DOI: 10.1053/j.gastro.2007.08.025] [Cited by in Crossref: 258] [Cited by in F6Publishing: 238] [Article Influence: 17.2] [Reference Citation Analysis]
109 Papatheodoridis GV, Chrysanthos N, Hadziyannis E, Cholongitas E, Manesis EK. Longitudinal changes in serum HBV DNA levels and predictors of progression during the natural course of HBeAg-negative chronic hepatitis B virus infection. J Viral Hepat. 2008;15:434-441. [PMID: 18194171 DOI: 10.1111/j.1365-2893.2007.00957.x] [Cited by in Crossref: 58] [Cited by in F6Publishing: 58] [Article Influence: 4.1] [Reference Citation Analysis]
110 Robotin MC, Kansil MQ, George J, Howard K, Tipper S, Levy M, Phung N, Penman AG. Using a population-based approach to prevent hepatocellular cancer in New South Wales, Australia: effects on health services utilisation. BMC Health Serv Res 2010;10:215. [PMID: 20663140 DOI: 10.1186/1472-6963-10-215] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 0.5] [Reference Citation Analysis]
111 Lee WJ, Wang W, Lee YC, Huang MT. Clinical characteristics and outcome of morbidly obese bariatric patients with concurrent hepatitis B viral infection. Obes Surg 2008;18:589-94. [PMID: 18330660 DOI: 10.1007/s11695-007-9346-1] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
112 Tong MJ, Hsu L, Chang PW, Blatt LM. Evaluation of current treatment recommendations for chronic hepatitis B: A 2011 update: Treatment guidelines for hepatitis B. Journal of Gastroenterology and Hepatology 2011;26:829-35. [DOI: 10.1111/j.1440-1746.2011.06623.x] [Cited by in Crossref: 25] [Cited by in F6Publishing: 19] [Article Influence: 2.3] [Reference Citation Analysis]
113 Liaw YF, Leung N, Kao JH, Piratvisuth T, Gane E, Han KH, Guan R, Lau GK, Locarnini S. Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2008 update. Hepatol Int. 2008;2:263-283. [PMID: 19669255 DOI: 10.1007/s12072-008-9080-3.] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
114 Cui F, Luo H, Wang F, Zheng H, Gong X, Chen Y, Wu Z, Miao N, Kane M, Hennessey K. Evaluation of policies and practices to prevent mother to child transmission of hepatitis B virus in China: results from China GAVI project final evaluation. Vaccine. 2013;31 Suppl 9:J36-J42. [PMID: 24331019 DOI: 10.1016/j.vaccine.2012.11.061] [Cited by in Crossref: 27] [Cited by in F6Publishing: 24] [Article Influence: 3.4] [Reference Citation Analysis]
115 Gaia S, Barbon V, Smedile A, Olivero A, Carenzi S, Lagget M, Alessandria C, Rizzetto M, Marzano A. Lamivudine-resistant chronic hepatitis B: an observational study on adefovir in monotherapy or in combination with lamivudine. J Hepatol. 2008;48:540-547. [PMID: 18279995 DOI: 10.1016/j.jhep.2007.12.018] [Cited by in Crossref: 30] [Cited by in F6Publishing: 27] [Article Influence: 2.1] [Reference Citation Analysis]
116 Fang X, Wu X, Li C, Zhou B, Chen X, Chen T, Yang F. Targeting selenium nanoparticles combined with baicalin to treat HBV-infected liver cancer. RSC Adv 2017;7:8178-85. [DOI: 10.1039/c6ra28229f] [Cited by in Crossref: 17] [Article Influence: 3.4] [Reference Citation Analysis]
117 Wu I, Shiffman M, Tong M, Marcellin P, Mondou E, Frederick D, Snow‐lampart A, Sorbel J, Rousseau F, Chang T. Sustained Hepatitis B e Antigen Seroconversion in Patients with Chronic Hepatitis B after Adefovir Dipivoxil Treatment: Analysis of Precore and Basal Core Promoter Mutants. CLIN INFECT DIS 2008;47:1305-11. [DOI: 10.1086/592570] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 0.8] [Reference Citation Analysis]
118 Liaw YF, Kao JH, Piratvisuth T, Chan HL, Chien RN, Liu CJ, Gane E, Locarnini S, Lim SG, Han KH. Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2012 update. Hepatol Int. 2012;6:531-561. [PMID: 26201469 DOI: 10.1007/s12072-012-9365-4] [Cited by in Crossref: 695] [Cited by in F6Publishing: 660] [Article Influence: 69.5] [Reference Citation Analysis]
119 Zhang JX, Lang JF, Liu YN. Combination therapy of lamivudine and hepatitis B vaccine for chronic hepatitis B: an analysis of 39 cases. Shijie Huaren Xiaohua Zazhi 2009; 17(6): 614-617 [DOI: 10.11569/wcjd.v17.i6.614] [Reference Citation Analysis]
120 Su QM, Ye XG. Effects of telbivudine and entecavir for HBeAg-positive chronic hepatitis B: A meta-analysis. World J Gastroenterol 2012; 18(43): 6290-6301 [PMID: 23180951 DOI: 10.3748/wjg.v18.i43.6290] [Cited by in CrossRef: 10] [Cited by in F6Publishing: 9] [Article Influence: 1.0] [Reference Citation Analysis]
121 Robinson DM, Scott LJ, Plosker GL. Entecavir: a review of its use in chronic hepatitis B. Drugs. 2006;66:1605-122; discussion 1605-122;. [PMID: 16956310 DOI: 10.2165/00003495-200666120-00009] [Cited by in Crossref: 19] [Cited by in F6Publishing: 20] [Article Influence: 1.2] [Reference Citation Analysis]
122 Ueda Y, Marusawa H, Ichinohe T, Kadowaki N, Uchiyama T, Chiba T. Effective treatment for de novo hepatitis B with nucleotide analogue in patients with hematological malignancies. Am J Hematol 2009;84:315-6. [PMID: 19350661 DOI: 10.1002/ajh.21388] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
123 Yuen MF, Lai CL. Recommendations and potential future options in the treatment of hepatitis B. Expert Opin Pharmacother 2006;7:2225-31. [PMID: 17059379 DOI: 10.1517/14656566.7.16.2225] [Reference Citation Analysis]
124 Spackman DE, Veenstra DL. A cost-effectiveness analysis of currently approved treatments for HBeAg-positive chronic hepatitis B. Pharmacoeconomics 2008;26:937-49. [PMID: 18850763 DOI: 10.2165/00019053-200826110-00006] [Cited by in Crossref: 23] [Cited by in F6Publishing: 23] [Article Influence: 1.8] [Reference Citation Analysis]
125 Sarin SK, Kumar M. Should chronic HBV infected patients with normal ALT treated: debate. Hepatol Int 2008;2:179-84. [PMID: 19669302 DOI: 10.1007/s12072-008-9065-2] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 0.9] [Reference Citation Analysis]
126 Wang H, Ru GQ, Yan R, Zhou Y, Wang MS, Cheng MJ. Histologic Disease in Chinese Chronic Hepatitis B Patients With Low Viral Loads and Persistently Normal Alanine Aminotransferase Levels. J Clin Gastroenterol 2016;50:790-6. [PMID: 27182648 DOI: 10.1097/MCG.0000000000000544] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.4] [Reference Citation Analysis]
127 Chan HL, Wong VW, Wong GL, Chim AM, Lai LH, Sung JJ. Evaluation of impact of serial hepatitis B virus DNA levels on development of hepatocellular carcinoma. J Clin Microbiol 2009;47:1830-6. [PMID: 19386857 DOI: 10.1128/JCM.00029-09] [Cited by in Crossref: 15] [Cited by in F6Publishing: 6] [Article Influence: 1.2] [Reference Citation Analysis]
128 Ku KC, Li J, Ha NB, Martin M, Nguyen VG, Nguyen MH. Chronic Hepatitis B Management Based on Standard Guidelines in Community Primary Care and Specialty Clinics. Dig Dis Sci 2013;58:3626-33. [DOI: 10.1007/s10620-013-2889-1] [Cited by in Crossref: 18] [Cited by in F6Publishing: 16] [Article Influence: 2.0] [Reference Citation Analysis]
129 Keeffe EB, Dieterich DT, Han SB, Jacobson IM, Martin P, Schiff ER, Tobias H. A Treatment Algorithm for the Management of Chronic Hepatitis B Virus Infection in the United States: 2008 Update. Clinical Gastroenterology and Hepatology 2008;6:1315-41. [DOI: 10.1016/j.cgh.2008.08.021] [Cited by in Crossref: 315] [Cited by in F6Publishing: 289] [Article Influence: 22.5] [Reference Citation Analysis]
130 Shouval D, Lai CL, Chang TT, Cheinquer H, Martin P, Carosi G, Han S, Kaymakoglu S, Tamez R, Yang J. Relapse of hepatitis B in HBeAg-negative chronic hepatitis B patients who discontinued successful entecavir treatment: the case for continuous antiviral therapy. J Hepatol. 2009;50:289-295. [PMID: 19070393 DOI: 10.1016/j.jhep.2008.10.017] [Cited by in Crossref: 75] [Cited by in F6Publishing: 76] [Article Influence: 5.4] [Reference Citation Analysis]
131 Bowden DS, Thompson AJ. New developments in HBV molecular diagnostics and quantitative serology. Hepatol Int. 2008;2:3-11. [PMID: 19669293 DOI: 10.1007/s12072-008-9051-8] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 0.4] [Reference Citation Analysis]
132 Huang ZB, Zhao SS, Huang Y, Dai XH, Zhou RR, Yi PP, Chen RC, Li WT, Zhang BX, Li N, Fan XG. Comparison of the efficacy of Lamivudine plus adefovir versus entecavir in the treatment of Lamivudine-resistant chronic hepatitis B: a systematic review and meta-analysis. Clin Ther 2013;35:1997-2006. [PMID: 24238791 DOI: 10.1016/j.clinthera.2013.10.002] [Cited by in Crossref: 14] [Cited by in F6Publishing: 11] [Article Influence: 1.6] [Reference Citation Analysis]
133 Papatheodoridis GV, Manolakopoulos S, Archimandritis AJ. Current treatment indications and strategies in chronic hepatitis B virus infection. World J Gastroenterol 2008; 14(45): 6902-6910 [PMID: 19058323 DOI: 10.3748/wjg.14.6902] [Cited by in CrossRef: 21] [Cited by in F6Publishing: 25] [Article Influence: 1.5] [Reference Citation Analysis]
134 Liu C, Kao J, Chen D. Kinetics of Hepatitis B Virus Reactivation After Chemotherapy: More Questions Than Answers. Gastroenterology 2006;131:1656. [DOI: 10.1053/j.gastro.2006.10.005] [Cited by in Crossref: 7] [Cited by in F6Publishing: 9] [Article Influence: 0.4] [Reference Citation Analysis]
135 Giaccone L, Festuccia M, Marengo A, Resta I, Sorasio R, Pittaluga F, Fiore F, Boccadoro M, Rizzetto M, Bruno B, Marzano A. Hepatitis B Virus Reactivation and Efficacy of Prophylaxis with Lamivudine in Patients Undergoing Allogeneic Stem Cell Transplantation. Biology of Blood and Marrow Transplantation 2010;16:809-17. [DOI: 10.1016/j.bbmt.2009.12.533] [Cited by in Crossref: 28] [Cited by in F6Publishing: 27] [Article Influence: 2.3] [Reference Citation Analysis]
136 Nüesch R, Ananworanich J, Srasuebkul P, Chetchotisakd P, Prasithsirikul W, Klinbuayam W, Mahanontharit A, Jupimai T, Ruxrungtham K, Hirschel B. Interruptions of tenofovir/emtricitabine-based antiretroviral therapy in patients with HIV/hepatitis B virus co-infection. AIDS. 2008;22:152-154. [PMID: 18090405 DOI: 10.1097/QAD.0b013e3282f303bf] [Cited by in Crossref: 25] [Cited by in F6Publishing: 16] [Article Influence: 1.8] [Reference Citation Analysis]
137 Singh NA, Reau N. Management of hepatitis B virus. Journal of Antimicrobial Chemotherapy 2008;62:224-8. [DOI: 10.1093/jac/dkn188] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
138 Hsieh MH, Ho CK, Hou NJ, Hsieh MY, Lin WY, Yang JF, Chiu CC, Huang JF, Chang NC, Wang CL. Abnormal liver function test results are related to metabolic syndrome and BMI in Taiwanese adults without chronic hepatitis B or C. Int J Obes (Lond). 2009;33:1309-1317. [PMID: 19752878 DOI: 10.1038/ijo.2009.172] [Cited by in Crossref: 17] [Cited by in F6Publishing: 19] [Article Influence: 1.3] [Reference Citation Analysis]
139 Kobashi H, Fujioka S, Kawaguchi M, Kumada H, Yokosuka O, Hayashi N, Suzuki K, Okanoue T, Sata M, Tsubouchi H, Sato C, Kiyosawa K, Tanikawa K, Seriu T, Ishikawa H, Takaki A, Iwasaki Y, Osawa T, Takaki T, Sakaguchi K, Shiratori Y, Yamamoto K, Tenney DJ, Omata M. Two cases of development of entecavir resistance during entecavir treatment for nucleoside-naive chronic hepatitis B. Hepatol Int 2009;3:403-10. [PMID: 19669367 DOI: 10.1007/s12072-008-9108-8] [Cited by in Crossref: 16] [Cited by in F6Publishing: 14] [Article Influence: 1.1] [Reference Citation Analysis]
140 Batirel A, Guclu E, Arslan F, Kocak F, Karabay O, Ozer S, Turanli M, Mert A. Comparable efficacy of tenofovir versus entecavir and predictors of response in treatment-naïve patients with chronic hepatitis B: a multicenter real-life study. Int J Infect Dis 2014;28:153-9. [PMID: 25286184 DOI: 10.1016/j.ijid.2014.09.004] [Cited by in Crossref: 26] [Cited by in F6Publishing: 23] [Article Influence: 3.3] [Reference Citation Analysis]
141 El-Zayadi AR, Badran HM, Saied A, Shawky S, Attia Mel-D, Zalata K. Evaluation of liver biopsy in Egyptian HBeAg-negative chronic hepatitis B patients at initial presentation: implications for therapy. Am J Gastroenterol. 2009;104:906-911. [PMID: 19293791 DOI: 10.1038/ajg.2009.30] [Cited by in Crossref: 17] [Cited by in F6Publishing: 13] [Article Influence: 1.3] [Reference Citation Analysis]
142 Bacq Y. Hépatite virale B et Grossesse. Gastroentérologie Clinique et Biologique 2008;32:S12-9. [DOI: 10.1016/s0399-8320(08)73260-3] [Cited by in Crossref: 19] [Cited by in F6Publishing: 5] [Article Influence: 1.4] [Reference Citation Analysis]
143 Hu TH, Tsai MC, Chen YT, Chien YS, Hung CH, Chen TC, Tseng PL, Chang KC, Yen YH. The therapeutic response of antiviral therapy in HBsAg-positive renal transplant recipients and a long-term follow-up. Hepatol Int. 2011;16. [PMID: 21744310 DOI: 10.1007/s12072-011-9295-6] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
144 Steinke JW, Illei G, Uzel G, Mican JM. Cytokine therapy. Clinical Immunology. Elsevier; 2008. pp. 1393-404. [DOI: 10.1016/b978-0-323-04404-2.10094-6] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
145 Kusumoto K, Yatsuhashi H, Nakao R, Hamada R, Fukuda M, Tamada Y, Taura N, Komori A, Daikoku M, Hamasaki K. Detection of HBV core promoter and precore mutations helps distinguish flares of chronic hepatitis from acute hepatitis B. J Gastroenterol Hepatol. 2008;23:790-793. [PMID: 18410611 DOI: 10.1111/j.1440-1746.2008.05391.x] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 1.2] [Reference Citation Analysis]
146 Chevaliez S, Pawlotsky JM. Diagnosis and management of chronic viral hepatitis: antigens, antibodies and viral genomes. Best Pract Res Clin Gastroenterol. 2008;22:1031-1048. [PMID: 19187865 DOI: 10.1016/j.bpg.2008.11.004] [Cited by in Crossref: 42] [Cited by in F6Publishing: 42] [Article Influence: 3.2] [Reference Citation Analysis]
147 Tran TT. Hepatitis B and pregnancy. Curr hepatitis rep 2009;8:91-5. [DOI: 10.1007/s11901-009-0013-y] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
148 Hui CK, Zhang HY, Bowden S, Locarnini S, Luk JM, Leung KW, Yueng YH, Wong A, Rousseau F, Yuen KY. 96 weeks combination of adefovir dipivoxil plus emtricitabine vs. adefovir dipivoxil monotherapy in the treatment of chronic hepatitis B. J Hepatol. 2008;48:714-720. [PMID: 18207280 DOI: 10.1016/j.jhep.2007.10.013] [Cited by in Crossref: 47] [Cited by in F6Publishing: 41] [Article Influence: 3.1] [Reference Citation Analysis]
149 Chen EQ, Huang FJ, He LL, Bai L, Wang LC, Zhou TY, Lei XZ, Liu C, Tang H. Histological changes in chinese chronic hepatitis B patients with ALT lower than two times upper limits of normal. Dig Dis Sci. 2010;55:432-437. [PMID: 19241166 DOI: 10.1007/s10620-009-0724-5] [Cited by in Crossref: 23] [Cited by in F6Publishing: 25] [Article Influence: 1.8] [Reference Citation Analysis]
150 Lin CL, Kao JH. To genotype or not to genotype: toward an optimal tailoring of treatment of chronic hepatitis B. Clin Infect Dis 2007;44:1665-6. [PMID: 17516416 DOI: 10.1086/518386] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
151 Lau G, Marcellin P, Peters M. Chronic hepatitis B: a global health problem requiring coherent worldwide treatment strategies. Hepatol Int 2007;1:316-25. [PMID: 19669356 DOI: 10.1007/s12072-007-9006-5] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 0.9] [Reference Citation Analysis]
152 Hosaka T, Suzuki F, Kobayashi M, Hirakawa M, Kawamura Y, Yastuji H, Sezaki H, Akuta N, Suzuki Y, Saitoh S. Development of HCC in patients receiving adefovir dipivoxil for lamivudine-resistant hepatitis B virus mutants. Hepatol Res. 2010;40:145-152. [PMID: 19788684 DOI: 10.1111/j.1872-034x.2009.00582.x] [Cited by in Crossref: 14] [Cited by in F6Publishing: 10] [Article Influence: 1.1] [Reference Citation Analysis]
153 Papatheodoridis GV, Deutsch M. Resistance issues in treating chronic hepatitis B. Future Microbiology 2008;3:525-38. [DOI: 10.2217/17460913.3.5.525] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 1.0] [Reference Citation Analysis]
154 Wong GL, Wong VW, Choi PC, Chan AW, Chim AM, Yiu KK, Chan H, Chan FK, Sung JJ, Chan HL. Evaluation of Alanine Transaminase and Hepatitis B Virus DNA to Predict Liver Cirrhosis in Hepatitis B e Antigen-Negative Chronic Hepatitis B Using Transient Elastography. The American Journal of Gastroenterology 2008;103:3071-81. [DOI: 10.1111/j.1572-0241.2008.02157.x] [Cited by in Crossref: 62] [Cited by in F6Publishing: 53] [Article Influence: 4.4] [Reference Citation Analysis]
155 Kimberlin DW. Antiviral Agents. Principles and Practice of Pediatric Infectious Diseases. Elsevier; 2018. pp. 1551-1567.e6. [DOI: 10.1016/b978-0-323-40181-4.00295-4] [Cited by in Crossref: 2] [Article Influence: 0.5] [Reference Citation Analysis]
156 Fried MW, Piratvisuth T, Lau GK, Marcellin P, Chow WC, Cooksley G, Luo KX, Paik SW, Liaw YF, Button P. HBeAg and hepatitis B virus DNA as outcome predictors during therapy with peginterferon alfa-2a for HBeAg-positive chronic hepatitis B. Hepatology. 2008;47:428-434. [PMID: 18220290 DOI: 10.1002/hep.22065] [Cited by in Crossref: 172] [Cited by in F6Publishing: 158] [Article Influence: 12.3] [Reference Citation Analysis]
157 Zhang H, Wu LY, Zhang S, Qiu LY, Li N, Zhang X, Zhang XZ, Shan CL, Ye LH, Zhang XD. Anti-hepatitis B virus X protein in sera is one of the markers of development of liver cirrhosis and liver cancer mediated by HBV. J Biomed Biotechnol. 2009;2009:289068. [PMID: 19746176 DOI: 10.1155/2009/289068] [Cited by in Crossref: 10] [Cited by in F6Publishing: 14] [Article Influence: 0.8] [Reference Citation Analysis]
158 Nguyen NH, Nguyen V, Trinh HN, Lin B, Nguyen MH. Treatment eligibility of patients with chronic hepatitis B initially ineligible for therapy. Clin Gastroenterol Hepatol 2013;11:565-71. [PMID: 23333662 DOI: 10.1016/j.cgh.2012.12.028] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 1.2] [Reference Citation Analysis]
159 Andreani T, Serfaty L, Poupon R, Chazouilleres O. Need to Strictly Define Hepatitis B Virus Immunotolerant Patients to Avoid Unnecessary Liver Biopsy. Gastroenterology 2008;135:2155-6. [DOI: 10.1053/j.gastro.2008.08.060] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.2] [Reference Citation Analysis]
160 Hadziyannis SJ, Vassilopoulos D. Telbivudine in the treatment of chronic hepatitis B. Expert Rev Gastroenterol Hepatol 2008;2:13-22. [PMID: 19072366 DOI: 10.1586/17474124.2.1.13] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
161 Lai M, Hyatt BJ, Nasser I, Curry M, Afdhal NH. The clinical significance of persistently normal ALT in chronic hepatitis B infection. J Hepatol. 2007;47:760-767. [PMID: 17928090 DOI: 10.1016/j.jhep.2007.07.022] [Cited by in Crossref: 211] [Cited by in F6Publishing: 198] [Article Influence: 14.1] [Reference Citation Analysis]
162 Chen EQ, He LL, Wang LC, Lei BJ, Bai L, Liu C, Lei XZ, Tang H. Change of liver histology in chronic hepatitis B patients with alanine aminotransferase less than two-time up limits of normal. Shijie Huaren Xiaohua Zazhi 2008; 16(22): 2476-2481 [DOI: 10.11569/wcjd.v16.i22.2476] [Reference Citation Analysis]
163 Kulkarni K, Jacobson IM, Tennant BC. The role of the woodchuck model in the treatment of hepatitis B virus infection. Clin Liver Dis. 2007;11:707-725, vii. [PMID: 17981226 DOI: 10.1016/j.cld.2007.08.012] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 1.0] [Reference Citation Analysis]
164 Lin MT, Chou YP, Hu TH, Yu HC, Hsu YC, Tsai MC, Tseng PL, Chang KC, Yen YH, Chiu KW. Telbivudine and adefovir combination therapy for patients with chronic lamivudine-resistant hepatitis B virus infections. Arch Virol. 2014;159:29-37. [PMID: 23857507 DOI: 10.1007/s00705-013-1786-4] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.2] [Reference Citation Analysis]
165 Levitsky J, Doucette K; the AST Infectious Diseases Community of Practice. Viral Hepatitis in Solid Organ Transplant Recipients. American Journal of Transplantation 2009;9:S116-30. [DOI: 10.1111/j.1600-6143.2009.02902.x] [Cited by in Crossref: 47] [Cited by in F6Publishing: 31] [Article Influence: 3.6] [Reference Citation Analysis]
166 Yu LH, Li N, Cheng SQ. The Role of Antiviral Therapy for HBV-Related Hepatocellular Carcinoma. Int J Hepatol. 2011;2011:416459. [PMID: 21994855 DOI: 10.4061/2011/416459] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 0.6] [Reference Citation Analysis]
167 Lim CY, Kowdley KV. Optimal duration of therapy in HBV-related cirrhosis. J Antimicrob Chemother. 2007;60:2-6. [PMID: 17483546 DOI: 10.1093/jac/dkm102] [Cited by in Crossref: 3] [Cited by in F6Publishing: 6] [Article Influence: 0.2] [Reference Citation Analysis]
168 Papatheodoridis GV, Manesis EK, Manolakopoulos S, Elefsiniotis IS, Goulis J, Giannousis J, Bilalis A, Kafiri G, Tzourmakliotis D, Archimandritis AJ. Is there a meaningful serum hepatitis B virus DNA cutoff level for therapeutic decisions in hepatitis B e antigen-negative chronic hepatitis B virus infection? Hepatology. 2008;48:1451-1459. [PMID: 18924246 DOI: 10.1002/hep.22518] [Cited by in Crossref: 89] [Cited by in F6Publishing: 84] [Article Influence: 6.4] [Reference Citation Analysis]
169 Hu KQ. Hepatitis B virus (HBV) infection in Asian and Pacific Islander Americans (APIAs): how can we do better for this special population? Am J Gastroenterol. 2008;103:1824-1833. [PMID: 18479498 DOI: 10.1111/j.1572-0241.2008.01878.x] [Cited by in Crossref: 46] [Cited by in F6Publishing: 48] [Article Influence: 3.3] [Reference Citation Analysis]
170 Keeffe EB, Dieterich DT, Pawlotsky JM, Benhamou Y. Chronic hepatitis B: Preventing, detecting, and managing viral resistance. Clin Gastroenterol Hepatol. 2008;6:268-274. [PMID: 18328434 DOI: 10.1016/j.cgh.2007.12.043] [Cited by in Crossref: 48] [Cited by in F6Publishing: 47] [Article Influence: 3.4] [Reference Citation Analysis]
171 Xiao Y, Wallace J, Thompson A, Hellard M, van Gemert C, Holmes JA, Croagh C, Richmond J, Papaluca T, Hall S, Hong T, Demediuk B, Iser D, Ryan M, Desmond P, Visvanathan K, Howell J. A qualitative exploration of enablers for hepatitis B clinical management among ethnic Chinese in Australia. J Viral Hepat 2021;28:925-33. [PMID: 33662159 DOI: 10.1111/jvh.13495] [Reference Citation Analysis]
172 Madej RM, Davis J, Holden MJ, Kwang S, Labourier E, Schneider GJ. International standards and reference materials for quantitative molecular infectious disease testing. J Mol Diagn 2010;12:133-43. [PMID: 20075208 DOI: 10.2353/jmoldx.2010.090067] [Cited by in Crossref: 52] [Cited by in F6Publishing: 40] [Article Influence: 4.3] [Reference Citation Analysis]
173 Gui HL, Wang H, Yang YH, Wu YW, Zhou HJ, Guo SM, Lin LY, Wang L, Cai W, Chen R, Guo Q, Zhou XQ, Bao SS, Xie Q. Significant histopathology in Chinese chronic hepatitis B patients with persistently high-normal alanine aminotransferase. J Viral Hepat 2010;17 Suppl 1:44-50. [PMID: 20586933 DOI: 10.1111/j.1365-2893.2010.01270.x] [Cited by in Crossref: 21] [Cited by in F6Publishing: 23] [Article Influence: 2.3] [Reference Citation Analysis]
174 Keeffe EB, Zeuzem S, Koff RS, Dieterich DT, Esteban-Mur R, Gane EJ, Jacobson IM, Lim SG, Naoumov N, Marcellin P. Report of an international workshop: Roadmap for management of patients receiving oral therapy for chronic hepatitis B. Clin Gastroenterol Hepatol. 2007;5:890-897. [PMID: 17632041 DOI: 10.1016/j.cgh.2007.05.004] [Cited by in Crossref: 194] [Cited by in F6Publishing: 182] [Article Influence: 12.9] [Reference Citation Analysis]
175 Zhang S, Ristau JT, Trinh HN, Garcia RT, Nguyen HA, Nguyen MH. Undertreatment of Asian chronic hepatitis B patients on the basis of standard guidelines: a community-based study. Dig Dis Sci 2012;57:1373-83. [PMID: 22466077 DOI: 10.1007/s10620-012-2137-0] [Cited by in Crossref: 26] [Cited by in F6Publishing: 25] [Article Influence: 2.6] [Reference Citation Analysis]
176 You J, Zhuang L, Cheng HY, Yan SM, Yu L, Huang JH, Tang BZ, Huang ML, Ma YL, Chongsuvivatwong V, Sriplung H, Geater A, Qiao YW, Wu RX. Efficacy of thymosin alpha-1 and interferon alpha in treatment of chronic viral hepatitis B: A randomized controlled study. World J Gastroenterol 2006; 12(41): 6715-6721 [PMID: 17075991 DOI: 10.3748/wjg.v12.i41.6715] [Cited by in CrossRef: 30] [Cited by in F6Publishing: 30] [Article Influence: 1.9] [Reference Citation Analysis]
177 Gambarin-Gelwan M. Hepatitis B in pregnancy. Clin Liver Dis. 2007;11:945-963, x. [PMID: 17981236 DOI: 10.1016/j.cld.2007.08.004] [Cited by in Crossref: 61] [Cited by in F6Publishing: 49] [Article Influence: 4.4] [Reference Citation Analysis]
178 Chaung KT, Ha NB, Trinh HN, Garcia RT, Nguyen HA, Nguyen KK, Garcia G, Ahmed A, Keeffe EB, Nguyen MH. High frequency of recurrent viremia after hepatitis B e antigen seroconversion and consolidation therapy. J Clin Gastroenterol 2012;46:865-70. [PMID: 22941429 DOI: 10.1097/MCG.0b013e31825ceed9] [Cited by in Crossref: 53] [Cited by in F6Publishing: 22] [Article Influence: 5.9] [Reference Citation Analysis]
179 Sohn HR, Min BY, Song JC, Seong MH, Lee SS, Jang ES, Shin CM, Park YS, Hwang JH, Jeong SH, Kim N, Lee DH, Kim JW. Off-treatment virologic relapse and outcomes of re-treatment in chronic hepatitis B patients who achieved complete viral suppression with oral nucleos(t)ide analogs. BMC Infect Dis. 2014;14:439. [PMID: 25125320 DOI: 10.1186/1471-2334-14-439] [Cited by in Crossref: 33] [Cited by in F6Publishing: 33] [Article Influence: 4.1] [Reference Citation Analysis]
180 Upadhyaya N, Chang R, Davis C, Conti MC, Salinas-Garcia D, Tang H. Chronic hepatitis B: perceptions in Asian American communities and diagnosis and management practices among primary care physicians. Postgrad Med. 2010;122:165-175. [PMID: 20861600 DOI: 10.3810/pgm.2010.09.2213] [Cited by in Crossref: 31] [Cited by in F6Publishing: 28] [Article Influence: 2.6] [Reference Citation Analysis]
181 Fontana RJ. Side effects of long-term oral antiviral therapy for hepatitis B. Hepatology. 2009;49:S185-S195. [PMID: 19399802 DOI: 10.1002/hep.22885] [Cited by in Crossref: 193] [Cited by in F6Publishing: 179] [Article Influence: 14.8] [Reference Citation Analysis]
182 Peck-radosavljevic M, Deutsch J, Ferenci P, Graziadei I, Hofer H, Holzmann H, Huber W, Laferl H, Maieron A, Stauber R, Vogel W. 4. Österreichischer Konsensusbericht zur Diagnose und Therapie der Hepatitis B 2009. Wien Klin Wochenschr 2010;122:280-302. [DOI: 10.1007/s00508-009-1298-0] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
183 Göbel T, Erhardt A, Herwig M, Poremba C, Baldus SE, Sagir A, Heinzel-Pleines U, Häussinger D. High prevalence of significant liver fibrosis and cirrhosis in chronic hepatitis B patients with normal ALT in central Europe. J Med Virol. 2011;83:968-973. [PMID: 21503908 DOI: 10.1002/jmv.22048] [Cited by in Crossref: 24] [Cited by in F6Publishing: 21] [Article Influence: 2.4] [Reference Citation Analysis]
184 Thomas HC. Best practice in the treatment of chronic hepatitis B: A summary of the European Viral Hepatitis Educational Initiative (EVHEI). Journal of Hepatology 2007;47:588-97. [DOI: 10.1016/j.jhep.2007.07.017] [Cited by in Crossref: 24] [Cited by in F6Publishing: 24] [Article Influence: 1.6] [Reference Citation Analysis]
185 Tillmann H, Patel K, McHutchison J. Hepatitis B virus viral load and treatment decision. Hepatology 2009;49:699; author reply 701-2. [PMID: 19177581 DOI: 10.1002/hep.22755] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
186 Fung J, Yuen MF, Yuen JC, Wong DK, Lai CL. Low serum HBV DNA levels and development of hepatocellular carcinoma in patients with chronic hepatitis B: a case-control study. Aliment Pharmacol Ther. 2007;26:377-382. [PMID: 17635372 DOI: 10.1111/j.1365-2036.2007.03390.x] [Cited by in Crossref: 30] [Cited by in F6Publishing: 30] [Article Influence: 2.0] [Reference Citation Analysis]
187 Liu C, Kao J. Hepatitis B virus genotype: What should the clinician know? Current Hepatitis Reports 2007;6:17-23. [DOI: 10.1007/bf02942174] [Cited by in Crossref: 6] [Article Influence: 0.4] [Reference Citation Analysis]
188 Min AD, Dienstag JL. Oral antivirals for chronic hepatitis B. Clin Liver Dis 2007;11:851-68, ix. [PMID: 17981232 DOI: 10.1016/j.cld.2007.08.003] [Cited by in Crossref: 18] [Cited by in F6Publishing: 14] [Article Influence: 1.3] [Reference Citation Analysis]
189 Van Damme P, Ward J, Shouval D, Wiersma S, Zanetti A. Hepatitis B vaccines. Vaccines. Elsevier; 2013. pp. 205-34. [DOI: 10.1016/b978-1-4557-0090-5.00025-2] [Cited by in Crossref: 14] [Article Influence: 1.6] [Reference Citation Analysis]
190 Yuan Y, Iloeje U, Li H, Hay J, Yao GB. Economic Implications of Entecavir Treatment in Suppressing Viral Replication in Chronic Hepatitis B (CHB) Patients in China from a Perspective of the Chinese Social Security Program. Value in Health 2008;11:S11-22. [DOI: 10.1111/j.1524-4733.2008.00362.x] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 1.3] [Reference Citation Analysis]
191 Schiff ER. Prevention of mortality from hepatitis B and hepatitis C. The Lancet 2006;368:896-7. [DOI: 10.1016/s0140-6736(06)69347-1] [Cited by in Crossref: 24] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]
192 Gish RG. Improving outcomes for patients with chronic hepatitis B. Hepatology Research 2007;37:S67-78. [DOI: 10.1111/j.1872-034x.2007.00108.x] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
193 Lee HW, Lee HJ, Hwang JS, Sohn JH, Jang JY, Han KJ, Park JY, Kim DY, Ahn SH, Paik YH, Lee CK, Lee KS, Chon CY, Han KH. Lamivudine maintenance beyond one year after HBeAg seroconversion is a major factor for sustained virologic response in HBeAg-positive chronic hepatitis B. Hepatology. 2010;51:415-421. [PMID: 19902424 DOI: 10.1002/hep.23323] [Cited by in Crossref: 91] [Cited by in F6Publishing: 79] [Article Influence: 7.6] [Reference Citation Analysis]
194 Hadziyannis SJ. Treatment paradigms on hepatitis B e antigen-negative chronic hepatitis B patients. Expert Opin Investig Drugs. 2007;16:777-786. [PMID: 17501691 DOI: 10.1517/13543784.16.6.777] [Cited by in Crossref: 24] [Cited by in F6Publishing: 23] [Article Influence: 1.6] [Reference Citation Analysis]
195 Barbosa-júnior FV, Sanchez-lermen RDL, Vieira KDA, de Oliveira RV, Souto FJ. Detection of hepatitis B activity in HBeAg-negative carriers with normal aminotransferase levels in central Brazil. Annals of Hepatology 2015;14:470-6. [DOI: 10.1016/s1665-2681(19)31168-8] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
196 Fung J, Lai CL, Yuen MF. New paradigms for the treatment of chronic hepatitis B. J Gastroenterol Hepatol. 2008;23:1182-1192. [PMID: 18637060 DOI: 10.1111/j.1440-1746.2008.05400.x] [Cited by in Crossref: 16] [Cited by in F6Publishing: 17] [Article Influence: 1.1] [Reference Citation Analysis]
197 Gaglio PJ, Sterling R, Daniels E, Tedaldi E; Terry Beirn Community Programs for Clinical Research on AIDS Hepatitis Working Group. Hepatitis B Virus and HIV Coinfection: Results of a Survey on Treatment Practices and Recommendations for Therapy. Clinical Infectious Diseases 2007;45:618-23. [DOI: 10.1086/520751] [Cited by in Crossref: 24] [Cited by in F6Publishing: 21] [Article Influence: 1.6] [Reference Citation Analysis]
198 Dienstag JL, Wei LJ, Xu D, Kreter B. Cross-study analysis of the relative efficacies of oral antiviral therapies for chronic hepatitis B infection in nucleoside-naive patients. Clin Drug Investig 2007;27:35-49. [PMID: 17177578 DOI: 10.2165/00044011-200727010-00003] [Cited by in Crossref: 11] [Cited by in F6Publishing: 13] [Article Influence: 0.7] [Reference Citation Analysis]
199 Pérez-Rodríguez MT, Sopeña B, Crespo M, Rivera A, Blanco TGD, Ocampo A, Martínez-Vázquez C. Clinical significance of “anti-HBc alone” in human immunodeficiency virus-positive patients. World J Gastroenterol 2009; 15(10): 1237-1241 [PMID: 19291824 DOI: 10.3748/wjg.15.1237] [Cited by in CrossRef: 21] [Cited by in F6Publishing: 21] [Article Influence: 1.6] [Reference Citation Analysis]
200 Liaw YF, Leung N, Kao JH, Piratvisuth T, Gane E, Han KH, Guan R, Lau GK, Locarnini S; Chronic Hepatitis B Guideline Working Party of the Asian-Pacific Association for the Study of the Liver. Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2008 update. Hepatol Int. 2008;2:263-283. [PMID: 19669255 DOI: 10.1007/s12072-008-9080-3] [Cited by in Crossref: 636] [Cited by in F6Publishing: 661] [Article Influence: 45.4] [Reference Citation Analysis]
201 Kumar M, Sarin SK, Hissar S, Pande C, Sakhuja P, Sharma BC, Chauhan R, Bose S. Virologic and histologic features of chronic hepatitis B virus-infected asymptomatic patients with persistently normal ALT. Gastroenterology. 2008;134:1376-1384. [PMID: 18471514 DOI: 10.1053/j.gastro.2008.02.075] [Cited by in Crossref: 250] [Cited by in F6Publishing: 241] [Article Influence: 17.9] [Reference Citation Analysis]
202 Tien PC, Kotler DP, Overton ET, Lewis CE, Rimland D, Bacchetti P, Scherzer R, Gripshover B; Study of Fat Redistribution and Metabolic Change in HIV Infection Investigators. Regional adipose tissue and elevations in serum aminotransferases in HIV-infected individuals. J Acquir Immune Defic Syndr 2008;48:169-76. [PMID: 18285711 DOI: 10.1097/QAI.0b013e3181685700] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.4] [Reference Citation Analysis]
203 Yao G, Chen C, Lu W, Ren H, Tan D, Wang Y, Xu D, Liu J, Xu D, Llamoso C. Virologic, serologic, and biochemical outcomes through 2 years of treatment with entecavir and lamivudine in nucleoside-naïve Chinese patients with chronic hepatitis B: a randomized, multicenter study. Hepatol Int. 2008;2:486-493. [PMID: 19669324 DOI: 10.1007/s12072-008-9088-8] [Cited by in Crossref: 15] [Cited by in F6Publishing: 21] [Article Influence: 1.1] [Reference Citation Analysis]
204 Nguyen MH, Garcia RT, Trinh HN, Lam KD, Weiss G, Nguyen HA, Nguyen KK, Keeffe EB. Histological Disease in Asian-Americans With Chronic Hepatitis B, High Hepatitis B Virus DNA and Normal Alanine Aminotransferase Levels. Am J Gastroenterol 2009;104:2206-13. [DOI: 10.1038/ajg.2009.248] [Cited by in Crossref: 47] [Cited by in F6Publishing: 42] [Article Influence: 3.6] [Reference Citation Analysis]
205 Chang K, Wu J, Hsu H, Chen H, Ni Y, Chang M. Entecavir Treatment in Children and Adolescents with Chronic Hepatitis B Virus Infection. Pediatrics & Neonatology 2016;57:390-5. [DOI: 10.1016/j.pedneo.2015.09.009] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.2] [Reference Citation Analysis]
206 ACT-HBV Asia Pacific Steering Committee Members. Chronic hepatitis B: treatment alert. Liver Int. 2006;26:47-58. [PMID: 18473475 DOI: 10.1111/j.1478-3231.2006.01374.x] [Cited by in Crossref: 27] [Cited by in F6Publishing: 16] [Article Influence: 1.9] [Reference Citation Analysis]
207 Scott JD, Mcmahon B. Role of combination therapy in chronic hepatitis B. Curr Gastroenterol Rep 2009;11:28-36. [DOI: 10.1007/s11894-009-0005-7] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
208 Nguyen MH, Keeffe EB. Are hepatitis B e antigen (HBeAg)-positive chronic hepatitis B and HBeAg-negative chronic hepatitis B distinct diseases? Clin Infect Dis. 2008;47:1312-1314. [PMID: 18840075 DOI: 10.1086/592571] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 0.6] [Reference Citation Analysis]
209 Tu WH, Zhu WJ, Qian F, Zhang JM, Zhu CW. Necessity of lowering the upper limit of normal of alanine aminotransferase in patients with chronic hepatitis B. Shijie Huaren Xiaohua Zazhi 2018; 26(30): 1765-1771 [DOI: 10.11569/wcjd.v26.i30.1765] [Reference Citation Analysis]
210 Gong X, Qin B, Ma Q. Relationship between adhesion molecules and virological response to pegylated interferon-alpha-2a treatment in patients with chronic hepatitis B: A pilot study: Predictive factors of IFN therapy. Hepatol Res 2014;44:1172-8. [DOI: 10.1111/hepr.12251] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
211 Fung J, Lai CL, Young J, Wong DK, Yuen J, Seto WK, Yuen MF. Quantitative hepatitis B surface antigen levels in patients with chronic hepatitis B after 2 years of entecavir treatment. Am J Gastroenterol. 2011;106:1766-1773. [PMID: 21826112 DOI: 10.1038/ajg.2011.253] [Cited by in Crossref: 48] [Cited by in F6Publishing: 45] [Article Influence: 4.4] [Reference Citation Analysis]
212 Jacobson IM. Combination therapy for chronic hepatitis B: ready for prime time? J Hepatol 2008;48:687-91. [PMID: 18331764 DOI: 10.1016/j.jhep.2008.02.006] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.2] [Reference Citation Analysis]
213 Licata A, Ingrassia D, Serruto A, Soresi M, Giannitrapani L, Montalto G, Craxì A, Almasio PL. Clinical course and management of acute and chronic viral hepatitis during pregnancy. J Viral Hepat 2015;22:515-23. [PMID: 25288051 DOI: 10.1111/jvh.12335] [Cited by in Crossref: 9] [Cited by in F6Publishing: 5] [Article Influence: 1.1] [Reference Citation Analysis]
214 Ye Q, Kam LY, Yeo YH, Dang N, Huang DQ, Cheung R, Nguyen MH. Substantial gaps in evaluation and treatment of patients with hepatitis B in the US. J Hepatol 2021:S0168-8278(21)02014-6. [PMID: 34474097 DOI: 10.1016/j.jhep.2021.08.019] [Reference Citation Analysis]
215 Koziel MJ, Peters MG. Viral hepatitis in HIV infection. N Engl J Med. 2007;356:1445-1454. [PMID: 17409326 DOI: 10.1056/nejmra065142] [Cited by in Crossref: 195] [Cited by in F6Publishing: 87] [Article Influence: 13.0] [Reference Citation Analysis]
216 Gupta S, Altice FL. Hepatitis B virus infection in US correctional facilities: a review of diagnosis, management, and public health implications. J Urban Health 2009;86:263-79. [PMID: 19184447 DOI: 10.1007/s11524-008-9338-z] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 1.3] [Reference Citation Analysis]
217 Kim MN, Lee CK, Ahn SH, Lee S, Kim SU, Kim DY, Kim HS, Han KH, Chon CY, Park JY. Maintaining remission in lamivudine-resistant patients with a virological response to adefovir add-on lamivudine after stopping lamivudine therapy. Liver Int 2014;34:1543-9. [PMID: 24330475 DOI: 10.1111/liv.12437] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 1.1] [Reference Citation Analysis]
218 Xie QL, Zhu Y, Wu LH, Fu LL, Xiang Y. The Efficacy and Safety of Entecavir and Interferon Combination Therapy for Chronic Hepatitis B Virus Infection: A Meta-Analysis. PLoS One. 2015;10:e0132219. [PMID: 26226455 DOI: 10.1371/journal.pone.0132219] [Cited by in Crossref: 9] [Cited by in F6Publishing: 13] [Article Influence: 1.3] [Reference Citation Analysis]
219 Kao JH. Role of viral factors in the natural course and therapy of chronic hepatitis B. Hepatol Int. 2007;1:415-430. [PMID: 19669337 DOI: 10.1007/s12072-007-9033-2] [Cited by in Crossref: 67] [Cited by in F6Publishing: 74] [Article Influence: 4.5] [Reference Citation Analysis]
220 Tran TT, Keeffe EB. Management of the pregnant hepatitis B patient. Curr hepatitis rep 2008;7:12-7. [DOI: 10.1007/s11901-008-0016-0] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
221 Fung J, Lai CL, Tanaka Y, Mizokami M, Yuen J, Wong DK, Yuen MF. The duration of lamivudine therapy for chronic hepatitis B: cessation vs. continuation of treatment after HBeAg seroconversion. Am J Gastroenterol. 2009;104:1940-1946; quiz 1947. [PMID: 19455108 DOI: 10.1038/ajg.2009.200] [Cited by in Crossref: 51] [Cited by in F6Publishing: 51] [Article Influence: 3.9] [Reference Citation Analysis]
222 Hoda K, Nguyen MH. Chronic hepatitis B virus infection in patients with “Normal” ALT levels. Current Hepatitis Reports 2007;6:24-9. [DOI: 10.1007/bf02942175] [Cited by in Crossref: 2] [Article Influence: 0.1] [Reference Citation Analysis]
223 Rajendra A, Wong JB. Economics of chronic hepatitis B and hepatitis C. Journal of Hepatology 2007;47:608-17. [DOI: 10.1016/j.jhep.2007.07.016] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 1.0] [Reference Citation Analysis]
224 Kao J, Chen D. Critical analysis of the immune tolerance phase of chronic HBV infection: Natural history and diagnosis. Curr hepatitis rep 2008;7:5-11. [DOI: 10.1007/s11901-008-0015-1] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.2] [Reference Citation Analysis]
225 Kohrt HE, Ouyang DL, Keeffe EB. Systematic review: lamivudine prophylaxis for chemotherapy-induced reactivation of chronic hepatitis B virus infection. Aliment Pharmacol Ther. 2006;24:1003-1016. [PMID: 16984494 DOI: 10.1111/j.1365-2036.2006.03081.x] [Cited by in Crossref: 83] [Cited by in F6Publishing: 75] [Article Influence: 5.5] [Reference Citation Analysis]
226 Lim SM, Jang JW, Kim BW, Choi H, Choi KY, Park SJ, Han CW. [Hepatitis B virus reactivation during chlorambucil and prednisolone treatment in an HBsAg-negative and anti-HBs-positive patient with B-cell chronic lymphocytic leukemia]. Korean J Hepatol 2008;14:213-8. [PMID: 18617769 DOI: 10.3350/kjhep.2008.14.2.213] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 0.4] [Reference Citation Analysis]
227 Dai CY, Tseng TC, Wong GL, Huang JF, Wong VW, Liu CJ, Yu ML, Chuang WL, Kao JH, Chan HL, Chen DS. Consolidation therapy for HBeAg-positive Asian chronic hepatitis B patients receiving lamivudine treatment: a multicentre study. J Antimicrob Chemother. 2013;68:2332-2338. [PMID: 23798667 DOI: 10.1093/jac/dkt193] [Cited by in Crossref: 1] [Cited by in F6Publishing: 8] [Article Influence: 0.1] [Reference Citation Analysis]
228 Levitsky J, Doucette K; the AST Infectious Diseases Community of Practice. Viral Hepatitis in Solid Organ Transplantation: Viral Hepatitis. American Journal of Transplantation 2013;13:147-68. [DOI: 10.1111/ajt.12108] [Cited by in Crossref: 56] [Cited by in F6Publishing: 46] [Article Influence: 6.2] [Reference Citation Analysis]
229 Moon YM, Hwang SG, Kim BS, Rim KS, Cho M, Kim DJ, Han JY, Kim YS, Choi HS, Ahn SH. [The efficacy and safety of telbivudine in korean patients with chronic hepatitis B]. Korean J Hepatol 2007;13:503-12. [PMID: 18159148 DOI: 10.3350/kjhep.2007.13.4.503] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.4] [Reference Citation Analysis]
230 Kim IH, Kim SH, Kim HC, Shin KD, Kim SW, Lee SO, Lee ST, Kim DG. [Effect of initial virologic response to adefovir on the development of resistance to adefovir in lamivudine-resistant chronic hepatitis B]. Korean J Hepatol 2007;13:349-62. [PMID: 17898551 DOI: 10.3350/kjhep.2007.13.3.349] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
231 Sobhonslidsuk A, Ungkanont A. A prophylactic approach for bone marrow transplantation from a hepatitis B surface antigen-positive donor. World J Gastroenterol 2007; 13(7): 1138-1140 [PMID: 17373754 DOI: 10.3748/wjg.v13.i7.1138] [Cited by in CrossRef: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
232 Chevaliez S, Pawlotsky JM. Interferons and their use in persistent viral infections. Handb Exp Pharmacol 2009;:203-41. [PMID: 19048202 DOI: 10.1007/978-3-540-79086-0_8] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 1.1] [Reference Citation Analysis]
233 Calvaruso V, Craxì A. Implication of normal liver enzymes in liver disease. Journal of Viral Hepatitis 2009;16:529-36. [DOI: 10.1111/j.1365-2893.2009.01150.x] [Cited by in Crossref: 32] [Cited by in F6Publishing: 27] [Article Influence: 2.5] [Reference Citation Analysis]